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Combining the Multitargeted Tyrosine Kinase Inhibitor
Vandetanib with the Antiestrogen Fulvestrant Enhances Its
Antitumor Effect in Non-small Cell Lung Cancer
Jill M. Siegfried, PhD, Christopher T. Gubish, MS, Mary E. Rothstein, BS, Cassandra Henry, BS,
and Laura P. Stabile, PhD
Introduction: Estrogen is known to promote proliferation and to
activate the epidermal growth factor receptor (EGFR) in non-small cell
lung cancer (NSCLC). Vascular endothelial growth factor (VEGF) is a
known estrogen responsive gene in breast cancer. We sought to deter-
mine whether the VEGF pathway is also regulated by estrogen in lung
cancer cells, and whether combining an inhibitor of the ER pathway
with a dual vascular endothelial growth factor receptor (VEGFR)/
EGFR inhibitor would show enhanced antitumor effects.
Methods: We examined activation of EGFR and expression of
VEGF in response to -estradiol, and the antitumor activity of the
multitargeted VEGFR/EGFR/RET inhibitor, vandetanib, when com-
bined with the antiestrogen fulvestrant both in vitro and in vivo.
Results: NSCLC cells expressed VEGFR-3 and EGFR. Vandetanib
treatment of NSCLC cells resulted in inhibition of EGFR and
VEGFR-3 and inhibition of -estradiol-induced P-MAPK activation,
demonstrating that vandetanib blocks -estradiol-induced EGFR sig-
naling. Treatment with -estradiol stimulated VEGFA mRNA and
protein (p  0.0001 over baseline), suggesting estrogenic signaling
causes heightened VEGFA pathway activation. This estrogenic induc-
tion of VEGFA mRNA seems largely dependent on cross-talk with
EGFR. Long-term vandetanib treatment also significantly increased
ER protein expression. The combination of vandetanib with fulves-
trant maximally inhibited cell growth compared with single agents (p
0.0001) and decreased tumor xenograft volume by 64%, compared with
51% for vandetanib (p  0.05) and 23% for fulvestrant (p  0.005).
Antitumor effects of combination therapy were accompanied by a
significant increase in apoptotic cells compared with single agents.
Conclusions: Fulvestrant may enhance effects of vandetanib in
NSCLC by blocking estrogen-driven activation of the EGFR pathway.
Key Words: EGFR, Estrogen, NSCLC, VEGF, VEGFR, Tyrosine
kinase inhibitor.
(J Thorac Oncol. 2012;7: 485–495)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer deaths in the United States and worldwide,
with a 15% 5-year survival rate for all stages combined.1
Currently, the best available first-line chemotherapy treat-
ment regimens for metastatic NSCLC achieve only a median
8- to 12-month survival time.2,3 Targeted therapies, such as
those inhibiting the epidermal growth factor receptor
(EGFR), have been introduced for second-line treatment of
NSCLC. Erlotinib is a tyrosine kinase inhibitor (TKI) target-
ing the EGFR, a receptor frequently expressed in NSCLC.
Erlotinib has demonstrated a high response rate and increased
survival in certain lung cancer patient populations such as
never smokers and those with EGFR mutations, and evidence
of activity in some patients with wild-type EGFR.4 Molecu-
larly targeted agents such as erlotinib show less toxicity
compared with chemotherapy. These drugs can improve sur-
vival in sensitive patients, but resistance often develops,
limiting clinical utility.4 Small molecule TKIs with a broader
spectrum of targets may be useful against tumors that show
high activity of more than one kinase known to promote
oncogenesis.
Tumor angiogenesis is the process leading to the for-
mation of blood vessels within a malignancy through stimu-
lation of endothelial cells. Angiogenesis plays a key role in
cancer cell survival, localized tumor growth, and metastases.5
Vascular endothelial growth factors (VEGFs) are potent mi-
togens for endothelial cells that activate the angiogenic
switch in vivo and enhance vascular permeability. Up-regu-
lation of VEGFs causes increased neovascularization in
many tumor types.6 There are several VEGF family mem-
bers known. VEGFA, the major form responsible for
angiogenesis, binds two distinct receptors in vascular cells,
vascular endothelial growth factor receptor (VEGFR)-1
and VEGFR-2, whereas VEGFB only recognizes VEGFR-1.7
VEGFR-2 is considered to be the dominant signaling receptor
for endothelial cell proliferation, permeability, and differen-
tiation in blood vessels.8 VEGFR-3 (also known as Flt-4) is
needed for angiogenesis that occurs in lymphatic endothelial
cells,9 and primarily recognizes the ligands VEGFC and
VEGFD. VEGFR-3 expression has also been detected in
gastric tumor cells10 and in lung tumor cells,11,12 where it
seems to be expressed along with VEGF ligands. Malignant
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cell proliferation and survival may be regulated in these
tumors by VEGFC or D in an autocrine manner.
Targeting VEGFR-3 in addition to VEGFR-2 may
inhibit actions of VEGF ligands on both endothelial and
tumor cells. Vandetanib is an orally active small molecule
anilinoquinazoline derivative that is a potent inhibitor of the
VEGFR-2 tyrosine kinase (IC50 40 nM) with additional
activity against EGFR (IC50 500 nM), VEGFR-3 (IC50 110
nM), and RET (IC50 130 nM).13 Although EGFR and
VEGFR pathways are commonly involved in NSCLC, the
RET gene does not seem to play a large role in lung cancer.
Vandetanib has shown activity against medullary thyroid
cancer, a disease in which the RET gene is frequently mu-
tated.14 Despite promising phase II results in lung cancer,
recently completed randomized phase III trials of vandetanib
in combination with pemetrexed (ZEAL) or docetaxel (ZO-
DIAC) or as a monotherapy versus erlotinib (ZEST) in
advanced lung cancer did not show increased overall survival
compared with any of these agents alone.15 Nevertheless,
there may be other settings in which vandetanib could be
effective against lung cancer when combined with other
targeted agents.
We have previously elucidated the role of estrogen
receptors (ERs) in NSCLC16 and have demonstrated cross-
talk between the ER and EGFR pathways in lung cancer.17
The primary means of cross-talk we detected in NSCLC was
due to release of EGFR ligands by estrogen which activated
the EGFR pathway.17 Others have reported an ER-EGFR
cross-talk in which ER can be phosphorylated by EGFR or
other kinases that converts it to an active signaling molecule
causing induction of estrogen responsive genes.18 EGFR
protein expression was also down-regulated in response to
-estradiol and up-regulated in response to fulvestrant. Fur-
thermore, the combination of the EGFR TKI gefitinib with
the antiestrogen fulvestrant reduced NSCLC proliferation and
increased apoptosis in vitro and in vivo, compared with either
agent alone. Furthermore, we have previously demonstrated
that ER is the main functional ER isoform involved in lung
cancer proliferation and signaling whereas ER is rarely
expressed.19 We recently completed a pilot phase I clinical
trial, which established the safety of combining gefitinib and
fulvestrant in postmenopausal women with advanced
NSCLC.20 The combination therapy proved safe and well
tolerated with a median progression-free survival of 12 weeks
and a median overall survival of 33 weeks, although gefitinib
has since been withdrawn as a treatment choice for lung
cancer in the United States. In a preliminary analysis, ER
positivity in at least 60% of tumor cells correlated with a
higher overall survival in patients treated with the combina-
tion. ER is expressed by 90% of both male and female
NSCLC,21 and EGFR-ER cross-talk may be an important
aspect of NSCLC growth. Because VEGFs are estrogen-
responsive genes in breast cancer,22 VEGFs may also be
regulated in part by the estrogen pathway in NSCLC. This
could be due to induction of VEGF gene expression by
activation of ER, activation of EGFR through ER cross-
talk, or both.
To address the potential of inhibiting multiple interde-
pendent growth-stimulatory pathways simultaneously in
NSCLC, here, we examine interaction between the main form
of estrogen, -estradiol, and VEGFs, and the antitumor ac-
tivity of the multitargeted VEGFR/EGFR inhibitor, vandet-
anib, when combined with the antiestrogen fulvestrant. Treat-
ment with -estradiol increased secretion of VEGFA in
NSCLC cells, which was largely mediated by ER activation
of the EGFR. Vandetanib could block -estradiol-induced
EGFR activation, and blockade with vandetanib led to up-
regulation of ER expression. The combination of fulvestrant
and vandetanib showed significantly increased antitumor ac-
tivity in NSCLC cells containing either wild-type EGFR or a
rare EGFR mutation not associated with enhanced sensitivity
to EGFR TKIs. Tumor growth in xenografts of NSCLC
containing wild-type EGFR was maximally inhibited by a
combination of vandetanib and fulvestrant. Malignant cells
within lung tumor xenografts were found to express the
receptors EGFR, VEGFR-3, and ER, whereas the receptor
VEGFR-2 was expressed by tumor vasculature. The ligands
-estradiol and VEGFA were also detected in xenografts.
These observations suggest that the interacting pathways
targeted by vandetanib and fulvestrant are present in prolif-
erating lung tumors. Using an antiestrogen to block both
estrogen-dependent stimulation of VEGFA expression and
estrogen-dependent activation of EGFR, and a possible up-
regulation of ER in response to EGFR inhibition, may
enhance the anticancer activity of vandetanib in lung cancer.
MATERIALS AND METHODS
Cell Lines and Reagents
201T and 273T cells were established as described
previously.23 A549, K562, and TT cells were purchased from
American Type Culture Collection (ATCC; Manassas, VA).
201T and A549 cells are wild-type for EGFR and EGFR TKI
resistant, whereas 273T cells contain a rare point mutation of
EGFR (Y727C), which shows minimal increased sensitivity
to EGFR TKIs.24 Human umbilical vein endothelial cells
(HUVEC) and A431 cell lysates were purchased from Santa
Cruz Biotechnology. Gefitinib was purchased from Chemi-
Tek (Indianapolis, IN). Fulvestrant was purchased from Toc-
ris (Ellisville, MO). Vandetanib was provided by AstraZen-
eca under a material transfer agreement. -estradiol was from
Sigma-Aldrich (St. Louis, MO). EGFR blocking antibody,
C225 was obtained from Imclone Systems, Inc. (New York,
NY). VEGF enzyme-linked immunosorbent assay (ELISA)
kits and recombinant human EGF were purchased from R&D
Systems (Minneapolis, MN). 201T, 273T, and A549 cells
were authenticated by short tandem repeat (STR) profiling
using the AmpFlSTR Identifiler PCR amplification kit (Ap-
plied Biosystems) within 6 months of performing the exper-
iments. K562 and TT cells were used in experiments after
purchase from ATCC within 6 months. ATCC authenticated
K562 and TT cells by STR profiling. TT cells were grown in
F-12K medium plus 10% fetal bovine serum (FBS), A549
cells were grown in BME 1% FBS, K562 cells were grown
in Iscove’s modified Dulbecco’s medium 10% FBS. 201T
and 273T cells were grown in BME 10% FBS.
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Protein Extraction and Western Analysis
Lung cancer cells or frozen tumor xenografts were
lysed in ice cold radioimmunoprecipitation buffer (10 mM
Tris-HCl [pH, 7.6], 50 mM NaCl, 5 mM EDTA, 50 mM NaF,
30 mM sodium pyrophosphate, 1 mM sodium vanadate, and
protease minitab) and sonicated. Insoluble material was re-
moved by centrifugation (14,000 rpm) for 10 minutes at 4°C.
Protein was separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, transferred onto nitrocellulose and
probed overnight at 4°C with primary antibody. Antibodies
used include the following: rabbit anti-VEGFR-2 (1:1000,
55B11; Cell Signaling Technology, Beverly, MA), mouse
monoclonal anti-Flt-4 (VEGFR-3) (1:200, D-6, Santa Cruz Bio-
technology, Santa Cruz, CA), rabbit anti-EGFR (1:500, 1005;
Santa Cruz Biotechnology), rabbit anti-RET (1:1000, 3220, Cell
Signaling Technology), mouse antiactin (1:10,000, Millipore,
Billerica, MA), rabbit anti-P-MAPK (1:1000, 9101; Cell Signal-
ing Technology), and rabbit anti-P-AKT (1:1000; 9271; Cell
Signaling Technology). Immunoreactivity was detected using
antimouse or antirabbit IgG conjugated peroxidase and visual-
ized by chemiluminescence.
For induction of P-MAPK and P-Akt, lung cancer
cells were grown to 75% confluency and serum deprived
for 48 hours. Cells were treated as described in the figure
legends. Protein extracts were prepared and analyzed as
described above. Primary antibodies were anti-P-MAPK
(1:1000, 9101; Cell Signaling Technology), anti-total
MAPK (T-MAPK) (1:1000, 9102; Cell Signaling Technol-
ogy), anti-P-AKT (1:1000; 9271; Cell Signaling Technol-
ogy), and anti-actin (1:10,000; Millipore). Quantitation
was done by densitometry and ImageQuaNT analysis and
expressed as the ratio of P-MAPK to T-MAPK or P-Akt to
-actin with control set to 100 or 1.
For detection of induction of ER protein, cells were
grown to 75% confluency in phenol-red free medium. Cells
were treated with vandetanib (2.5 M) or DMSO control in
phenol-red free medium with 1% charcoal stripped serum and
replenished daily for 7 days. Protein extracts were prepared
on days 1, 4, and 7 as described above. Primary antibody was
rabbit anti-ER (1:1000, clone 68–4, Millipore). The blot
was stripped and reprobed with actin antibody. Quantitation
was done by densitometry and ImageQuaNT analysis and
expressed as the ratio of ER to actin. No treatment on day
1 was set to 1.
VEGF ELISAs
Cells were treated as indicated in the figures. Cell
culture supernatant was removed and equal amounts were
analyzed in duplicate following the manufacturers’ instruc-
tions using a human VEGFA, VEGFC, or VEGFD Quan-
tikine ELISA kit that detects the specific VEGF isoform, with
no reactivity against other VEGF isoforms. Total protein was
used to normalize all ELISA data.
RNA Extraction and Reverse Transcriptase
Polymerase Chain Reaction
Cells were serum starved for 48 hours and then treated
with 10 nM -estradiol from 0 to 24 hours. In Figure 3C, cells
were pretreated with inhibitors as indicated followed by
treatment with 10 nM -estradiol for 1 hour. mRNA was
isolated using RNeasy purification kit (Qiagen, Valencia,
CA) and reverse transcriptase polymerase chain reaction
(RT-PCR) was performed using OneStep RT-PCR kit (Qia-
gen) with human VEGFA primer pair (BioChain Institute,
Inc., Hayward, CA) and GAPDH as a control. Quantitation
was performed using the Kodak Image Station and image
analysis software.
Cell Viability Assay
Cells were plated in 96 well plates at a density of 4 
103 cells/well and allowed to attach overnight. The cells were
washed with phosphate-buffered saline (PBS) and incubated
in serum-free phenol red-free medium for 48 hours. Treat-
ments were added as indicated in the figure legends for 72
hours. Cell viability was monitored using the CellTiter 96
Aqueous One Solution Cell Proliferation Assay Kit (Promega
Corporation, Madison, WI) following the manufacturer’s in-
structions. Absorbance values at 490 nm were recorded 1
hour after addition of the CellTiter 96 Aqueous One Solution
Reagent using a Wallac Victor2 1420 Multilabel Counter and
readings were directly proportional to the amount of cellular
proliferation. Control was set to 100 and all results were
expressed relative to control.
In Vivo Tumor Xenograft Model
Female C.B.-17 scid 4- to 5-week old mice were
obtained from Charles River (Wilmington, MA) and 201T
lung tumor cells were harvested and suspended in sterile,
serum-free PBS supplemented with 50% Matrigel (BD Bio-
sciences, San Jose, CA). Cells (2  106) were injected in the
hind flank region of each mouse, one site per mouse and
allowed to grow. Six days after tumor implantation, the mice
were divided into four treatment groups (10 mice per group):
placebo, fulvestrant, vandetanib, and fulvestrant plus vande-
tanib. Treatment began 6 days after tumor implantation and
lasted for 4 weeks. Fulvestrant (30 mg/kg) or vehicle control
(peanut oil) was injected s.c. twice a week. Vandetanib (12.5
mg/kg) was administered daily by oral gavage at a volume of
0.2 mL/mouse. Tumor size was measured weekly and re-
ported as an average relative tumor volume calculated as (l
w  h  )/2 (mm3), where l is the length, w is the width,
and h is the height of the tumor measured with calipers. At
the end of the treatment period, the animals were killed and
the tumors were removed and fixed in 10% buffered formalin
for immunostaining. In a separate experiment, treatments
were administered for 2 weeks and tumors were removed and
frozen for protein isolation 2 hours after final treatment.
Animal care was in strict compliance with the institutional
guidelines established by the University of Pittsburgh.
Apoptosis Assay
The number of apoptotic cells was determined using the
ApopTag Peroxidase In Situ Apoptosis Detection Kit (Milli-
pore) as described previously.25 Brown staining was consid-
ered positive. Slides were read and scored for the number of
positive tumor cells per five high-powered fields per sample.
Results are reported as the mean  SE.
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Immunohistochemistry and
Immunofluorescence
Slides were deparaffinized with xylenes and rehydrated
before heat-induced antigen retrieval. Nonspecific binding
was blocked for 10 to 45 minutes at room temperature.
Sections were incubated with primary antibodies for
VEGFR-2 (1:50, Cell Signaling Technology, Clone 55B11),
PECAM (1:100, Santa Cruz Biotechnology, Clone M-20),
-estradiol (prediluted from BioGenex, AR038-5R) as de-
scribed,26 ER (1:25, Santa Cruz Biotechnology, Clone
H-150), P-ER (1:50, Abcam, ab62257), EGFR (1:500,
DAKO, Clone H11), and VEGFA (1:100, Santa Cruz Bio-
technology, Clone C-1) in PBS 0.5% BSA at 4°C over-
night. For fluorescent staining, sections were incubated with
conjugated fluorescent secondary antibodies at a 1:500 dilu-
tion (Donkey Anti-Goat 546 and Donkey-Anti-Rabbit 488,
Invitrogen) for 1 hour at room temperature and staining was
visualized using confocal microscopy (Lecia TCSSL). Immu-
noreactivity for immunohistochemistry was detected using
biotinylated IgG secondary antibodies specific for each pri-
mary antibody followed by incubation with diaminobenzidine
chromogenic substrate.
Statistical Analysis
Biochemical and animal data were analyzed using un-
paired Student t test with or without Welch correction or
analysis of variance as indicated in the figure legends (Graph-
pad Instat 3.06, GraphPad Software, Inc, San Diego, CA). All
statistical tests were two sided with the threshold for statis-
tical significance defined as p  0.05.
RESULTS
NSCLC Cells Express 2 of the Targets of
Vandetanib and VEGFA
Three NSCLC cell lines, 201T and A549 (derived from
adenocarcinomas) and 273T (derived from a squamous cell
carcinoma), were examined by immunoblot for expression of
the vandetanib targets VEGFR-2, VEGFR-3, EGFR, and
RET (Figure 1A). An appropriate positive control was used
for each protein (VEGFA stimulated HUVEC for VEGFR-2,
K562 erythroleukemia cells for VEGFR-3, A431 squamous
cell carcinoma cells for EGFR, and TT thyroid medullary
carcinoma cells for RET). All three NSCLC cell lines were
positive for EGFR and VEGFR-3 and negative for VEGFR-2
and RET. VEGFR-2 negativity was confirmed by immuno-
precipitation compared with positive control VEGFA-treated
HUVEC cells. Ability of vandetanib to inhibit EGFR was
shown by examining activation of MAPK in response to 10
ng/ml EGF, which we have previously documented is a rapid
signaling response to EGFR activation in NSCLC cells.17
Vandetanib produced a complete inhibition of phospho-
MAPK after EGF (10 ng/ml) treatment in 201T, 273T, and
A549 cells at a concentration of 2.5 M or more (Figure 1B).
Activation of Akt in response to 100 ng/ml VEGFC was used
to determine if the kinase of VEGFR-3 was also blocked by
vandetanib in these cells. A concentration of 5 M vandet-
anib completely blocked the phosphorylation of Akt induced
by VEGFC in 201T cells (Figure 1C). Complete inhibition of
P-Akt was also observed in 273T and A549 cells (data not
shown). Thus both EGFR and VEGFR-3 are potential targets
of vandetanib in NSCLC cells.
Because VEGFR-2 is the major endothelial VEGFR
responsible for angiogenesis in blood vessels, and is the most
sensitive target of vandetanib, we also examined conditioned
media from NSCLC cells for VEGFA, the main VEGFR-2
ligand (Figure 1D). Over time in nonconfluent culture, pro-
liferating NSCLC cells secreted increasing amounts of
VEGFA protein as detected by VEGFA-specific ELISA, up
to 1200 pg/ml at 48 hours, after correcting for cell prolifer-
ation. Results are shown for 201T cells but similar VEGF
production was also detected in 273T and A549 cells. Be-
cause VEGFR-3 responds to VEGFC and D, we also mea-
sured these VEGF ligands over time using specific ELISA
assays. No VEGFD protein was detected in conditioned
medium collected over a 48 hours period from any of the
three cells lines. VEGFC secretion into conditioned medium
was detected in these cell lines, and the amount secreted
significantly increased over 48 hours after correcting for cell
proliferation (Supplemental Figure 1) but was over 15-fold
lower (75 pg/ml at 48 hours) than the amount of VEGFA
produced. This suggests that there may be some autocrine
stimulation of VEGFR-3 in these NSCLC cells, but the
VEGFR-2 ligand VEGFA is the main form of VEGF secreted
by NSCLC cells.
VEGFA Is an Estrogen-Responsive Gene in
NSCLC
VEGFs are known to contain estrogen response ele-
ments and to be transcriptionally activated by estrogen in
breast cancer.22 We previously documented expression of
ERs in NSCLC. Full-length ER mRNA and protein were
found in all three of the lung cancer cell lines used here
whereas full-length ER was undetectable.16 We examined
relative expression of VEGFA mRNA and protein over time
in the presence of 10 nM -estradiol, a physiologic concen-
tration, in 201T cells (Figure 2A, B). VEGFA mRNA de-
tected by quantitative RT-PCR peaked at 1 hour after treat-
ment with -estradiol, and the 2.2-fold increase over baseline
was significant at both 1 hour (p  0.001) and 2 hours (p 
0.0001). The amount of VEGFA protein secreted into culture
media, detected by ELISA, was also enhanced by -estradiol
1.7-fold over control at 4 hours (p  0.0001), and this effect
persisted at 6 hours. Similar results in estrogen-induced
VEGFA secretion were also observed in 273T and A549 cells
(Supplemental Figure 2A). In contrast, we observed a small
but not significant increase in VEGFC protein production
after similar -estradiol treatment, and VEGFD was still
undetectable in conditioned medium from lung cancer cell
lines after treatment with -estradiol (data not shown). The
ability of estrogen to increase production of VEGFA in lung
cancer cells may produce heightened angiogenesis mediated
by VEGFR-2 in endothelial cells in the tumor microenviron-
ment, whereas VEGFR-3 activity controlled by VEGFC pro-
duction by lung cancer cells may not be affected by estrogen.
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Vandetanib Inhibits ER-EGFR Cross-Talk in NSCLC
We have previously demonstrated that nongenomic
signaling of -estradiol, primarily through the ER, results in
activation of proteases that cleave EGFR ligands such as
TGF-, which is followed by EGFR-driven activation of
MAPK within 5 minutes.17,19 This MAPK activation can be
blocked by EGFR TKIs.17 To determine if vandetanib can
also block ER-EGFR cross-talk, we determined the phos-
phorylation status of MAPK after exposure to 10 nM -es-
tradiol in the presence and absence of vandetanib and com-
pared it to inhibition with two positive controls, gefitinib and
an EGFR neutralizing antibody, C225. Phosphorylation of
MAPK was quantitated relative to total MAPK using densi-
tometry and expressed as a percent of vehicle control (Figure
3A). Treatment with -estradiol for 5 minutes resulted in a
twofold induction of phospho-MAPK (significant compared
with vehicle, p  0.0001), which was significantly inhibited
by 2 hours pretreatment with 10 M vandetanib (p 
0.0002), comparable to the positive controls gefitinib and
C225. Vandetanib alone was not significantly different from
vandetanib plus -estradiol. This shows that vandetanib can
prevent activation of EGFR that is initiated by estrogen. This
result was replicated in the other two cell lines (not shown).
We also previously showed that long-term exposure to an
EGFR TKI can induce ER protein expression in NSCLC,
providing a feedback mechanism that could increase ER
signaling during EGFR inhibition.17 We determined that the
multikinase inhibitor vandetanib also induced expression of
FIGURE 1. Protein expression in non-small cell lung cancer (NSCLC) cell lines and vascular endothelial growth factor (VEGF)
secretion. A, Western blot analysis for VEGFR-2, VEGFR-3, epidermal growth factor receptor (EGFR), RET, and actin in whole
cell lysates (50 g) from NSCLC cells 201T, 273T, and A549. Cell line controls were specific for each protein of interest: VEGF
stimulated HUVEC (VEGFR-2), K562 (VEGFR-3), A431 (EGFR), and TT (RET). B, 201T, 273T, and A549 cells were serum starved
for 48 hours followed by treatment with 10 ng/ml EGF, 2.5 M vandetanib or the combination followed by Western blot
analysis for P-MAPK and T-MAPK. Representative images are shown and relative densitometric quantitation is shown below
each blot. C, Vandetanib inhibits phosphorylation of Akt. Serum starved 201T cells were treated with VEGFC (100 ng/mL) for
30 minutes to induce downstream phosphorylation of Akt, followed by treatment with increasing concentrations of vandet-
anib. 201T cells treated with EGF (10 ng/ml) for 5 minutes was used for a positive control. D, VEGFA is secreted in lung tumor
cells over time in culture. 201T cells were plated at time 0. Media was removed over time up to 48 hours and analyzed using
VEGF Quantikine enzyme-linked immunosorbent assay (ELISA) kit. Data were normalized to total protein at each time point
and are represented as relative secretion compared with control time 0. Results represent the mean  SE per time point. *p 
0.01; ***p  0.0001 analyzed by Student t test.
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ER protein in NSCLC (Figure 3B). ER detected by im-
munoblot increased fourfold over vehicle treatment at 4 days
(p  0.02) and sevenfold over vehicle treatment of 7 days
(p  0.02), after correction for amount of actin, following
administration of 2.5 M vandetanib. Blocking the EGFR
with vandetanib may increase estrogenic signaling in
NSCLC.
We then examined to what extent stimulation of
VEGFA mRNA expression by -estradiol occurred down-
stream of EGFR activation, because EGFR is known to
transcriptionally regulate VEGF production,27,28 and we pre-
viously found that nongenomic signaling of ER through
EGFR activation predominated over nuclear signaling of
ER through an estrogen response element in lung cancer
cells.16,19 Vandetanib and the positive control EGFR TKI
gefitinib were used to inhibit EGFR before and during treat-
ment with -estradiol. Fulvestrant was also used to block
ER, and the combined effect of fulvestrant and each TKI
was also examined. Induction of VEGFA mRNA by -estra-
diol was inhibited 75% by either gefitinib, vandetanib, or
fulvestrant alone, and 100% (return to baseline) by the com-
bination of either gefitinib or vandetanib with fulvestrant
(Figure 3C). These findings suggest that ER nongenomic
signaling to the EGFR is largely involved in VEGFA induc-
tion in NSCLC cells, although some VEGFA induction may
occur through direct ER genomic signaling.
Combination Treatment with Vandetanib and
Fulvestrant Shows Increased Antiproliferative
Effects
We next determined the effect of combining vandetanib
(at approximately the IC50 concentration for 201T and A549
cells determined from concentration-response curves) with
the antiestrogen fulvestrant to increase the antiproliferative
effect of vandetanib. Fulvestrant blocks the binding of -es-
tradiol to ER and we have previously shown has modest
antiproliferative effects against NSCLC cells in culture as a
single agent.17 Cells were serum deprived and then stimulated
to proliferate with a combination of -estradiol and EGF as
described in Materials and Methods. We have previously
shown that -estradiol enhances the proliferative effects of
EGF.19 In 201T and A549 cells (Figure 4), the combination of
vandetanib and fulvestrant decreased relative cell prolifera-
tion in 201T cells from 43% of vehicle control with vandet-
anib alone to 26% of control with the combination (p 
0.0001). In A549 cells, relative cell proliferation decreased
from 70% of control with vandetanib alone to 18% of control
with the combination (p  0.0001). Fulvestrant alone, which
shows a maximum antiproliferative effect of 70% of control
at the highest concentration that is soluble (20 M), had only
weak antiproliferative effects at the 5 M concentration used
for the combination study (83 and 96% of control in 201T and
A549 cells, respectively). Similar results were also observed
in 273T cells with the maximum inhibition observed with the
combination treatment (Supplemental Figure 2B). Compara-
ble enhancement of antiproliferative effects was observed
when the two agents were combined at concentrations rang-
ing from 1 to 5 M (data not shown).
Vandetanib and Fulvestrant in Combination
Maximally Inhibited Growth of NSCLC
Xenografts
We confirmed the enhancement of vandetanib and
fulvestrant in combination in an in vivo tumor growth exper-
iment (Figure 5A). 201T cells were injected s.c. into immu-
nocompromised mice and treatments were started after estab-
lishment of tumor xenografts at 7 days. Fulvestrant reduced
mean tumor volume by 23% compared with vehicle control
(n.s.), whereas vandetanib reduced mean tumor volume by
51% compared with vehicle (p  0.005). The combination
reduced mean tumor volume by 64% (p  0.000l compared
with vehicle, p  0.05 compared with vandetanib alone, and
p  0.005 compared with fulvestrant alone). No toxicities,
such as weight loss, loss of appetite, dehydration, or skin-
FIGURE 2. Estrogen induces vascular endothelial growth factor (VEGF) mRNA production and protein secretion. A, 201T cells
were serum starved for 48 hours and then treated with 10 nM -estradiol from 0 to 24 hours. mRNA was isolated using
RNeasy purification kit and reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using OneStep RT-PCR kit
with human VEGF primer pair. Results are the mean  SE of two separate experiments each of which had two samples per
time point. Control was set to 100. **p  0.001; ***p  0.0001, Student t test. B, 201T cells were treated with 10 nM -es-
tradiol for 0 to 6 hours. Media was collected at each time point and analyzed using a Quantikine VEGF enzyme-linked immu-
nosorbent assay (ELISA) kit. Total protein was isolated from each well and quantitated. Results were normalized for total pro-
tein and are expressed relative to the time 0 control. Results are representative of the mean  SE of two separate experiments
each of which had three samples per treatment group. ***p  0.0001, Student t test.
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related toxicities because of treatment were observed in the
animals throughout the entire length of the experiment.
Extent of apoptosis in tumor xenografts was examined
by immunohistochemistry of formalin-fixed excised tumors
(Figure 5B); staining of apoptotic nuclei was increased by
both single and combination treatments. The number of
apoptotic cells was quantitated in sections from five tumors
per treatment group (Figure 5C), showing a significant in-
crease in apoptotic cells with combination treatment (mean of
32.5 cells/field) compared with vehicle (mean 2.5 cells/field,
p  0.0001), and compared with vandetanib alone (mean
22.5 apoptotic cells/field, p  0.01), or fulvestrant alone
(mean 14 cells/field, p 0.0001). Single treatments were also
significantly different from vehicle control (Figure 5C).
Confirmation that NSCLC In Vivo Express the
Targets of Vandetanib and Fulvestrant
Xenografts were also examined to confirm expression
of the targets of the agents used in vivo (Figure 6). Endothe-
lial cells within lung tumor xenografts were positive for the
endothelial cell marker PECAM (red, Figure 6A) and were
also positive for the vandetanib target VEGFR-2 (green,
Figure 6A). Dual-label immunofluorescence showed overlay
of PECAM and VEGFR-2 staining (yellow, Figure 6A),
FIGURE 3. Vandetanib inhibits estrogen-induced P-MAPK and increased ER protein expression. A, Serum-deprived 201T
cells were pretreated for 2 hours with vandetanib (10 M), gefitinib (20 M), and C225 (epidermal growth factor receptor
[EGFR] blocking antibody, 6 g/ml) or not treated at all followed by stimulation with 10 nM -estradiol for 5 minutes; Repre-
sentative Western blot. Each sample was analyzed by Western analysis using an anti-P-MAPK antibody and anti-T-MAPK anti-
body. No treatment was set to 100. Quantitative results represent the mean  S.E. of results of four samples per experimental
treatment. Unpaired Student t test, Welch corrected, compared with control, ***p  0.0008. Treatment groups plus estrogen
compared with estrogen alone, ***p  0.0001, **p  0.0002, *p  0.0039, and n.s., nonsignificant. B, 201T cells were
treated with 2.5 M vandetanib or DMSO control in phenol-red free medium with 1% charcoal stripped serum for up to 7
days. A representative Western blot is shown of ER and actin expression. No treatment on day 1 was set to 1. Quantitation
represents the mean  S.E. of four samples per experimental treatment, normalized to actin control. Unpaired Student t test,
Welch corrected, *p  0.02. C, 201T cells were pretreated with gefitinib (20 M), vandetanib (10 M), or fulvestrant (5 M)
for 2 hours followed by treatment with 10 nM -estradiol for 1 hour. mRNA was isolated and analyzed as in Figure 2A. Results
are the mean  SE of two separate experiments each of which had two samples per time point. Control was set to 100.
***p  0.0001, **p  0.001.
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demonstrating that VEGFR-2 protein is localized within tu-
mor blood vessels.
Tumor cells within xenografts were also positive for
two of the vandetanib targets, EGFR and VEGFR-3 (Figure
6B), whereas being negative for VEGFR-2 (not shown), as
expected from immunoblots of cell cultures (Figure 1A).
Tumors were also positive for ER (Figure 6B), as previously
published,17 and for its ligand -estradiol suggesting active
signaling (Figure 6B). Recently, Meireles et al.26 has demon-
strated that -estradiol can be specifically detected in using
immunohistochemical techniques. Two endpoints were used
to demonstrate changes in ER-EGFR interaction following
treatments: the amount of VEGFA produced and the presence
of phospho-ER. ER can be phosphorylated by EGFR
kinase signaling after which it is transported to the nucleus.
Phosphorylated ER positive nuclei were observed from all
treatment groups, with the least amount observed in the
combination treatment group: control  35.8  4.3, fulves-
trant 28.6 3.9, vandetanib 23.0 4.4, combination
17.6  4.8 positive nuclei per 200 mM area (control versus
combination p  0.05, all other comparisons n.s.). Xeno-
grafts were also positive for VEGFA (Figure 6C), the ligand
for VEGR-2. Staining of VEGFA within xenografts was very
diffuse, being present both within tumor cells and in the
interstitial spaces, consistent with it being a secreted protein.
A semiquantitative scale was therefore used to compare
VEGFA staining among different treatments, to determine if
inhibitors reduced VEGFA content, as predicted from the cell
culture experiments. Below each image is the relative value
of the overall VEGFA staining in each group, scored on a
FIGURE 4. Effect of combined treatment of
fulvestrant and vandetanib on cell proliferation.
201T and A549 cells were serum deprived for
48 hours followed by treatment with fulves-
trant (5 M) and/or vandetanib (1.25 M) as
indicated for 72 hours. All treatment groups
received EGF (10 ng/ml) and -estradiol (10
nM) for 72 hours. Cellular proliferation was
measured using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay. Cell Titer Re-
agent (20 L) was added to each well and
plates were incubated for 1 hour. Results repre-
sent the mean  S.E. of 16 samples per experi-
mental treatment. ***p  0.0001, unpaired
Student t test, Welch corrected, compared
with control, and for fulvestrant and vandet-
anib treated data compared with the combina-
tion treated data.
FIGURE 5. Combined fulvestrant and
vandetanib treatment maximally inhib-
its tumor growth in mice. A, 201T tu-
mor bearing mice received the follow-
ing treatments for 4 weeks: vehicle
control, fulvestrant (30 mg/kg), vande-
tanib (12.5 mg/kg), or combination.
Treatment began 6 days after tumor
implantation. Results represent the
mean tumor volumes  S.E. of 9 to 10
tumors per treatment group. Unpaired
Student t test, Welch corrected. *p 
0.05; **p  0.005; ***p  0.0001. B,
Representative immunohistochemical
images of apoptotic cells in tumors
from different treatment groups at
20 magnification. C, Quantitative re-
sults. Positive cells were counted in five
high-magnification areas per xenograft
from five samples per treatment group.
The results are presented as the mean
number of apoptotic cells per area 
SE. Unpaired Student t test; *p  0.01;
**p  0.001; and ***p  0.0001.
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scale of 1 to 5, 1 being staining observed in fewer than
10% of cells with low intensity and 5 being staining
observed in 90% or more of cells and most intense staining.
Treatment with the antiestrogen fulvestrant reduced relative
staining for VEGFA compared with vehicle (Figure 6C,
second panel). VEGFA staining was reduced to a greater
extent by treatment with vandetanib and also by the combi-
nation (Figure 6C, two right panels), suggesting that loss of
VEGFA is involved in the antitumor effects of both fulves-
trant and vandetanib. Positive and negative control staining is
shown in Supplemental Figure 3. Evidence that ER-EGFR
cross-talk was also affected was seen by a decrease in the
extent of phospho-MAPK labeling in xenografts with com-
bination treatment (not shown). In combination treatment,
inhibition of ER and EGFR interaction is likely to be
involved in the enhancement by fulvestrant of antitumor
effects of vandetanib.
Targeted Agents Modulate Signaling within
Xenografts
To show that cell signaling is modulated within the
xenografts after short-term exposure to targeted agents, in a
separate experiment protein lysates were prepared from lung
tumor xenografts 2 hours after the last treatment and analyzed
for phospho-Akt and phospho-MAPK (Supplemental Figure 4).
Three individual tumors from each treatment group were ana-
lyzed. Phospho-Akt and phospho-MAPK expression were de-
creased in each individual treatment group with the lowest
expression in the tumors from the combination treatment group
(61% inhibition of phospho-Akt and 64% inhibition of phospho-
MAPK with combination treatment).
DISCUSSION
Combining targeted therapies in specific lung cancer
patients with predicted sensitivity may increase efficacy of
these agents. Understanding which oncogenic targets are
present in lung cancer and how these pathways interact may
also help to individualize drug therapy. Here, we show that
the antitumor effect of the multikinase inhibitor vandetanib
can be enhanced by addition of the antiestrogen fulvestrant, a
drug that is well tolerated and has shown activity in treatment
of ER-positive breast cancer.29–31 Enhanced antitumor effects
were observed in cell culture with isolated NSCLC cells that
FIGURE 6. Expression of vandetanib and fulvestrant targets in tumor cells or blood vessels within tumor xenografts. A, Rep-
resentative image of VEGFR-2 expression in endothelial cells. Dual-label immunofluorescence staining was performed on tu-
mor xenograft tissue sections for the detection of VEGFR-2 (green) and PECAM (red). Colocalization of VEGFR-2 with endothe-
lial cells is seen in the merged image. Areas of yellow represent colocalization. B, Representative immunohistochemical
staining of -estradiol, ER, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor
(VEGFR)-3 in lung tumor xenografts. C, VEGFA is reduced by treatment in lung tumor xenografts. Representative staining from
each treatment group is shown. Below each image is the relative value of the overall VEGFA staining in each group, scored on
a scale of 1 to 5, 1 being staining observed in fewer than 10% of cells with low intensity and 5 being staining ob-
served in 90% or more of cells and most intense staining.
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are ER positive16 and in a xenograft model containing tumor
vasculature. We showed that in NSCLC cell lines that are
positive for several targets of vandetanib (EGFR and
VEGFR-3 and the VEGFR-3 ligand VEGFC) increased an-
tiproliferative effects can be achieved in cell culture with the
combination of vandetanib and fulvestrant. VEGFA, an im-
portant ligand for VEGFR-2 (the major VEGFR family mem-
ber found in endothelial cells), was also found to be released
by NSCLC cells under the control of the ER pathway and
enhanced VEGFA secretion appeared to be mainly down-
stream of an estrogen-dependent activation of EGFR, which
could be maximally inhibited by combining agents targeting
EGFR and ER. In tumor xenografts, an increased antitumor
effect of these two inhibitors was also observed. The presence
of VEGFR-2 on vasculature in the tumor microenvironment
suggests that this additional target for vandetanib, which can
respond to VEGFA released by -estradiol stimulation may
also be relevant to the increased antitumor effect. Lung tumor
xenografts were found to express both ER and -estradiol.
We have demonstrated previously that ER is found both in
the cytoplasmic compartment and the nuclear compartment in
lung tumors and that cytoplasmic ER protein expression is
an independent negative predictor of overall survival in
NSCLC, consistent with the cytoplasmic ER staining ob-
served here.19,21 We have also found that the phosphorylated
form of ER is mainly nuclear and is maximally decreased by
the combination. Using fulvestrant and vandetanib together to
inhibit ER-EGFR cross-talk may result in a greater reduction
in proliferation and a reduction in the activity of the VEGFA-
VEGFR2 pathway involved in angiogenesis. The ability of
vandetanib to inhibit VEGFR-3 expressed by tumor cells may
also contribute to its antitumor effects.
Vandetanib has recently shown promise in the treat-
ment of medullary thyroid cancer, a disease in which the RET
gene, a key target of vandetanib, is frequently mutated or
over-expressed through gene amplification.13,14,32 Vandetanib
showed some promising results in phase II trials in lung
cancer, but randomized phase III trials in combination with
other agents such as pemetrexed and docetaxel did not show
increased overall survival, as summarized in a recent report.15
Nevertheless, there may be a subset of lung cancer patients
that might respond to vandetanib combinations, particularly if
the combination inhibited complementary signaling targets.
Recent findings from the Biomarker-integrated Approaches
of Targeted Therapy for Lung Cancer Elimination (BATTLE)
trial shows that vandetanib treatment was beneficial in pa-
tients with EGFR mutation/amplification or VEGF/VEGFR2
expression.33 Our preclinical data support a possible role for
a combination of vandetanib with an antiestrogen such as
fulvestrant to achieve greater antitumor effects in lung
tumors expressing ER, -estradiol, VEGFR-2, VEGFA,
and EGFR. An EGFR mutation that sensitizes to erlotinib
or gefitinib was not required to see an enhanced effect. An
increased antitumor effect was observed using cells lack-
ing an EGFR mutation that sensitizes the receptor to EGFR
TKIs. The mechanism of increased antitumor effect seems
to involve inter-related ER-EGFR signaling and modula-
tion of VEGFR-2 signaling.
A concern with vandetanib is the toxicity profile, which
includes diarrehea, rash, acne, nausea, hypertension, head-
ache, and rare but potentially dangerous prolongation of the
QT interval.14 Fulvestrant can be given for long periods and
can exhibit toxicities relating to withdrawal of estrogen, such
as hot flashes.29–31 Because fulvestrant and vandetanib have
nonoverlapping toxicities, fulvestrant would not be expected
to increase the toxicity of vandetanib. Our previous phase I
study showed no increased toxicity of gefitinib in combina-
tion with fulvestrant in advanced lung cancer.20
Many studies have now demonstrated that estrogen
receptors are frequently expressed in NSCLC,33,34 along with
the enzyme aromatase,21,35,36 resulting in high intratumoral
concentrations of -estradiol.37 ERs, especially ER proba-
bly mediate several protumor effects in lung cancer including
increased proliferation, reduced apoptosis, and increased an-
giogenesis. The gene for VEGFA, a major angiogenic pro-
tein, is known to contain an ERE that can mediate ER-
induced gene transcription directly.22 In addition, EGFR
signaling through Akt is known to lead to induction of
VEGFA transcription,27 probably involving activation of the
transcription factor Sp1.38 Direct stimulation by estrogen of
VEGFA transcription by means of an ERE or indirect stim-
ulation by means of ER-EGFR cross-talk are both possible in
NSCLC cells, although our data support a major role for
nongenomic activation of EGFR in mediating this effect.
Fulvestrant and vandetanib may limit the amount of VEGFA
that is available in addition to having a direct effect to block
a group of receptors important for stimulating tumor growth.
One of the disappointments of EGFR TKIs is their
relatively low activity against lung cancer that lacks an EGFR
sensitizing mutation. Combination therapy might be a strat-
egy to improve responses in these cases, which represent the
majority of lung cancer. Selection of patients with high tumor
expression of several targets of vandetanib, and ligands for
these targets, and coexpression of ER and -estradiol might
improve the likelihood of seeing clinical responses to the
combination of vandetanib and an antiestrogen such as ful-
vestrant. Because ER cross-activates EGFR and each of
these receptors seems to be induced when the other is inhib-
ited (as shown in Ref. 17 and data presented here), the
combination of vandetanib and fulvestrant might also prevent
induction of a compensatory mechanism that could limit
effectiveness of either compound alone.
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